Abstract Body

The male genital tract (MGT) is a putative HIV reservoir and potential barrier to cure. Tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and emtricitabine (FTC) are widely-used NRTIs. Seminal mononuclear cell (SMC) concentrations (C) of TDF, TAF, and FTC may inform effective dosing regimens for HIV cure.

8 HIV+, 8 HIV- men receiving TDF/FTC and 4 HIV+ men receiving TAF/FTC for clinical care provided 6 blood (BP) and seminal plasma (SP) samples to construct a composite 24hr C curve. TFV diphosphate (TFVdp), FTC triphosphate (FTCtp), deoxyadenosine triphosphate (dATP), and deoxycytidine triphosphate (dCTP) were measured in peripheral blood mononuclear cells (PBMC) and SMC; SMC for 12 men were pooled due to low cell counts. For PBMC/SMC C below the limit of quantification (LOQ), ½ of the sample LOQ was imputed. Noncompartmental analysis (Phoenix Win Nonlinv6.3, Certara) generated BP and SP area under the curves (AUC) for SP:BP ratios. C over 24h (C[sub]ss,ave[/sub]) was computed for each analyte. Data are reported as median (IQR).

Age, BMI for the HIV+ men was 40 (34, 47) yrs and 28.5 (25.8, 32.9) kg/m2. Age, BMI for the HIV- men was 30.5 (24, 39) yrs and 28.3 (23.9, 32.1) kg/m2. All had eGFR >50 mL/min. HIV+ TDF men had 39% higher SP C than HIV- TDF men. TAF C were also detected for longer post-dose in SP (12h) than in BP (6h), although they were 80% lower than in BP. TFV SP:BP AUC ratios after TDF dosing were 1.6 (0.8,4.7) [HIV+] and 1.1 (0.8, 2.4) [HIV-]; and 9.4 (7.7, 12) after TAF dosing. Css,ave are in the table. Despite low TFV C in BP with TAF, TFV SP C were similar to SP C in HIV- TDF men. As expected, TFVdp PBMC C with TAF were 4-fold higher than with TDF. SMC TFVdp C were 94% higher with TAF than with TDF. FTC SP:BP ratios were ≥3; FTC SP C in HIV+ men were 30-60% higher than HIV- men; FTCtp SMC C were 8-fold higher with TAF. Small changes in median dATP and dCTP SMC C between groups were seen.

High TFV C in SP after TAF dosing was unexpected. Cathepsin A in the MGT and differing drug transporter affinities for TAF and TFV may explain these findings. Increased SMC TFVdp C after TAF dosing may reflect both high TFV penetration and increased PBMC C; these data suggest TAF’s MGT distribution differs from TDF. Differing SP/SMC C between HIV+/HIV- men and TFV dosage form suggest drug and disease-specific mechanisms of MGT penetration.